Setmelanotide Production Cost Reports

The report provides a detailed analysis essential for establishing a setmelanotide production plant. It encompasses all critical aspects necessary for setmelanotide production, including the cost of setmelanotide production, setmelanotide plant cost, setmelanotide production costs, and the overall setmelanotide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a setmelanotide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Setmelanotide is an innovative injectable medication that is administered daily under the skin. It works as targeted therapy for chronic weight management in individuals with obesity stemming from rare genetic disorders affecting the brain's hunger control system. It is FDA-approved for adults and children aged 2 years and older who have confirmed loss-of-function mutations in the POMC, PCSK1, or LEPR genes. It is also used for Bardet-Biedl syndrome (BBS), which is another rare genetic condition involving MC4R pathway issues. It shows good results like average weight reductions of 25% or more in responders over a year, along with improvements in quality of life. It treats the root cause of these monogenic obesities instead of just managing the symptoms.

The market of setmelanotide is influenced by its usage in rare genetic obesity disorders like POMC, PCSK1, and LEPR deficiencies. The rising prevalence of these conditions, increased R&D funding, like 25% NIH boost over five years, fuels its market. The advancements in personalised medicine and gene therapy, along with supportive policies like the Orphan Drug Act and expanded healthcare budgets for rare diseases supports its market. The supply chain disruptions and raw material challenges that increase costs and delay availability, regulatory approvals, and production scale-up needs impact industrial setmelanotide procurement.  Also, high orphan drug pricing, emerging therapy competition, and patient adherence further affect its sourcing strategies.

Raw Material for Setmelanotide Production

According to the setmelanotide production plant project report, the key raw materials used in the production of setmelanotide include Fmoc Rink amide resin and Fmoc protected amino acids for the setmelanotide sequence.

Production Process of Setmelanotide

The extensive setmelanotide production cost report consists of the following major industrial production process:

1. From Fmoc solid phase peptide synthesis: The production of setmelanotide starts with a linear peptide chain on a solid support (Fmoc Rink amide resin). This used standard Fmoc solid phase peptide synthesis to attach each protected amino acid in sequence. The completed linear peptide, still attached to the resin, is then treated in cold organic solvent with an oxidising agent (iodine) so that the two cysteine residues form a disulfide bond directly on the resin, giving the cyclic peptide. The excess iodine is quenched with a reducing agent, the resin is washed, and the cyclised peptide is cleaved from the resin and fully deprotected using a strong acid mixture (TFA based). The crude peptide is precipitated with ether and then purified to get solid setmelanotide.

Setmelanotide is a cyclic octapeptide melanocortin-4 receptor (MC4R) agonist that has a molecular formula of C49H68N18O9S2 and a molecular weight of 1117.3 g/mol (free base). It has a complex structure with 18 nitrogen atoms, 2 sulfur atoms, multiple amide bonds, and defined stereochemistry. It has a heavy atom count of 79–82, with computed hydrogen bond donors and acceptors supports its receptor binding affinity. It is supplied as a lyophilised white powder stable under refrigeration. It has low water solubility, which is typical of peptides, and requires reconstitution for subcutaneous injection. It has a short plasma half-life because of enzymatic degradation.